Benevolent is a London-based artificial intelligence company focused on drug discovery and development. Since its inception, the company has raised $282 million across multiple funding rounds, including a significant $90 million Series C round, to build and scale its AI-driven biomedical research platform. Benevolent applies generative AI and machine learning to uncover disease mechanisms, identify drug targets, and accelerate therapeutic development across human and veterinary medicine.